Adocia ADR | |
Stock Exchange | Other OTC |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
6.92 M |
Public Float |
- |
Adocia | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
6.92 M |
Public Float |
- |
Adocia | |
Stock Exchange | Euronext Paris |
EPS |
EUR0.96 |
Market Cap |
EUR131.08 M |
Shares Outstanding |
6.92 M |
Public Float |
3.91 M |
Address |
115 avenue Lacassagne Lyon Rhone-Alpes 69003 France |
Employees | - |
Website | http://www.adocia.com |
Updated | 07/08/2019 |
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: BioChaperone Lispro; BioChaperone Combo; HinsBet; BioChaperone Human Glucagon; BioChaperone Glargine GLP-1; and BioChaperone Prandaial Combinations for T1D. The company was founded by Gérard, Olivier, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France. |